Eli Lilly reported phase 3 results showing its triple-agonist retatrutide produced unprecedented mean weight loss in clinical testing. The company disclosed average body-weight reductions reaching the high‑20s percent range at late timepoints, with accompanying improvements in osteoarthritis knee pain reported in the dataset. Data releases and media coverage (MedCity News, BioCentury) also flagged higher discontinuation rates and unusual skin reactions that elevated safety and tolerability questions. Investors and competitors are recalibrating product expectations after Lilly’s disclosures; analysts described the results as raising the efficacy bar for next‑generation obesity therapeutics. Trial investigators and company statements emphasized both the magnitude of weight loss and the need to parse side‑effect profiles across dose cohorts. Clinicians will watch regulatory filings and full datasets to assess benefit–risk and patient selection strategies.